Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company that develops personalized immune therapies for cancer. Founded in 1996 and headquartered in Bethesda, Maryland, the company uses a dendritic‑cell platform to activate patients’ own immune systems. Its flagship product, DCVax‑L, is in Phase III trials for glioblastoma multiforme, while DCVax‑Direct is in Phase I/II trials for various inoperable solid tumors. Additional candidates include DCVax for late‑stage ovarian cancer and DCVax‑Prostate, which has received U.S. FDA clearance. Clinical studies have shown that these therapies can extend time to recurrence and overall survival, improve quality of life, and reduce side‑effects compared with conventional treatments.